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Abstract
Glycosaminoglycans (GAGs) are frequently associated with amyloid deposits in most amyloid diseases, and there is evidence
to support their active role in amyloid fibril formation. The purpose of this study was to obtain structural insight into GAG-
protein interactions and to better elucidate the molecular mechanism underlying the effect of GAGs on the amyloid
aggregation process and on the related cytotoxicity. To this aim, using Fourier transform infrared and circular diochroism
spectroscopy, electron microscopy and thioflavin fluorescence dye we examined the effect of heparin and other GAGs on
the fibrillogenesis and cytotoxicity of aggregates formed by the amyloidogenic W7FW14 apomyoglobin mutant. Although
this protein is unrelated to human disease, it is a suitable model for in vitro studies because it forms amyloid-like fibrils
under physiological conditions of pH and temperature. Heparin strongly stimulated aggregation into amyloid fibrils,
thereby abolishing the lag-phase normally detected following the kinetics of the process, and increasing the yield of fibrils.
Moreover, the protein aggregates were harmless when assayed for cytotoxicity in vitro. Neutral or positive compounds did
not affect the aggregation rate, and the early aggregates were highly cytotoxic. The surprising result that heparin induced
amyloid fibril formation in wild-type apomyoglobin and in the partially folded intermediate state of the mutant, i.e., proteins
that normally do not show any tendency to aggregate, suggested that the interaction of heparin with apomyoglobin is
highly specific because of the presence, in protein turn regions, of consensus sequences consisting of alternating basic and
non-basic residues that are capable of binding heparin molecules. Our data suggest that GAGs play a dual role in
amyloidosis, namely, they promote beneficial fibril formation, but they also function as pathological chaperones by
inducing amyloid aggregation.
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Introduction
Amyloid diseases are related to anomalies in the folding process
of certain proteins that may form insoluble fibril deposits. They
include over 20 clinically relevant disorders, among which
neurodegenerative disorders such as Alzheimer’s disease, and
non neuropathic conditions such as type-II diabetes [1]. Amyloid
fibrils share common structural features despite the considerable
diversity in the primary sequence of the constituent proteins. They
are rich in b-sheet structures and the ordered regions adopt the
classic cross-b structure in which individual strands in the b-sheets
run perpendicular to the long axis of the fibril with the inter b-
sheet hydrogen bonds oriented parallel to the fibril axis [2–4]. A
wide range of proteins and peptides that do not form amyloid in
vivo can be induced to do so in vitro and this has led to the
hypothesis that the ability to form amyloid is a general property of
polypeptide chains [3]. Amyloid fibril formation in bulk solution
occurs through a nucleation-dependent polymerization process
consisting of two phases, i.e., nucleation and extension. The initial
step of nucleus formation consists in the association of monomers.
This process is thermodynamically unfavorable and is the rate-
limiting step of the fibrillation process. Once a nucleus has formed,
the further addition of monomers to the nucleus becomes
thermodynamically favorable and results in rapid extension of
amyloid fibrils in vitro [5]. The exact nature of the pathogenic
amyloid species is matter of intense debate, but there is increasing
evidence that oligomers or intermediates rather than fibrils are
responsible for cytotoxicity and the associated cell death in
amyloid diseases [6–8]. One therapeutic option is to design small
molecules to block aggregation or to stabilize benign oligomers
formed on or off the amyloid formation pathway [9,10]. However,
there is evidence that promoting the formation of insoluble
aggregates could lower the concentration of the toxic oligomers or
intermediates associated with disease and thus protect against
damage [11–13].
Recently, attention has focused on the effect of the biological
environment in which aggregation occurs naturally. In fact, the
biological milieu can profoundly influence the mechanism and rate
of process, as well as the structure and stability of the resulting
fibrils [14]. In particular, considerable effort has been devoted to
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aggregation. Structurally, GAGs are a group of negatively charged
heterogeneous polysaccharides resulting from the assembly of
repeating disaccharide units and are one of the main components
of the extracellular matrix [15,16]. In most amyloid diseases,
GAGs are often associated with amyloid deposits, and there is
evidence that they play an active role in favoring amyloid fibril
formation and stabilization [17–20]. Snow and Kisilevsky [21]
reported an increase in GAG levels at the time of serum amyloid A
deposition. More recently, it was demonstrated that inhibition of
heparan sulfate biosynthesis is directly correlated with loss of
amyloid deposition in amyloid A animal models [22–24]. Evidence
for the relation between GAGs and amyloid comes also from in
vitro studies. GAGs stimulate, in vitro, the formation of amyloid
fibrils from the Alzheimer Ab protein [25–27]; heparin and, to a
lesser extent, heparan sulfate have been reported to increase
significantly the rate of fibrillation of tau protein, a-synuclein,
gelsolin, AcP, b2-microglobulin and the aortic amyloid polypep-
tide medin [28–34]. Heparan sulfate has also been found to
convert the prion protein from the PrP
C to the PrP
SC form [35].
Generally, among GAGs, heparin is particularly effective in
accelerating fibril formation probably because of its high content
of sulfate groups [25]. Several studies have demonstrated that
electrostatic interactions are important in the binding of heparin to
amyloid fibrils. In particular, removal of all sulfate groups from
heparin or the addition of magnesium or calcium ions suppresses
these interactions, thereby indicating their electrostatic nature
[25,32]. Moreover, it has been postulated that the amyloid-
promoting activity of heparin is facilitated through specific amyloid
polypeptide-heparin interactions via binding sites [36–43].
Notwithstanding the large body of data associating heparin and
other GAGs with amyloidogenesis, little is known about the
mechanism by which heparin promotes amyloid formation or
about its effect on the overall aggregation pathway. It has been
supposed that, similarly to catalyzed reactions, GAGs favour
aggregation, nucleation and amyloid fibril formation by a
mechanism substantially different from that occurring in bulk
solution [44]. The data available suggest that heparin can
influence and promote the misfolding of polypeptides into
proamyloidogenic intermediates rich in b-sheet and may also
function as a structural template for self-assembly. Recent studies
on acetyl phosphatase have shown that heparin sulfate induces
changes in the aggregation process by splitting it in a parallel
manifold faster pathway [45]. Moreover, heparin accelerates
transthyretin (TTR) aggregation by a scaffold-based mechanism in
which the sulfate groups interact primarily with TTR oligomers
through electrostatic interactions, by concentrating and orienting
the oligomers and, subsequently, facilitating the formation of
higher molecular weight aggregates [46].
We previously showed that a mutated form of apomyoglobin,
i.e., W7FW14F, undergoes a nucleation-dependent polymeriza-
tion reaction that results in the formation of amyloid fibrils
identical to those formed by proteins involved in amyloid diseases
[47,48]. Although the W7FW14F apomyoglobin mutant is
unrelated to any human disease, it is a suitable model for amyloid
aggregation studies because it forms amyloid-like fibrils under
physiological conditions of pH and temperature. Under these
experimental conditions, wild-type apomyoglobin is in the
globular, a-helical native state. In the present study, we used
W7FW14F apomyoglobin to study the effect of GAGs, mainly
heparin and related compounds on the various kinetic phases of
W7FW14F apomyoglobin amyloid aggregation. The results show
that both the extent and rate of formation of amyloid fibrils are
greatly enhanced by heparin and certain other GAGs, but not by
the neutral and positively charged polymers dextran and
polylysine. The amyloid aggregates formed in the presence of
heparin appear to be harmless. Thus, heparin eliminates cytotoxic
oligomeric species by promoting the formation of benign fibrils.
Interestingly, we found that heparin induces early toxic aggregates
also in wild-type apomyoglobin (a protein that does not show any
tendency to aggregate). This could open a debate regarding the
therapeutic use of heparin.
Materials and Methods
Materials and Protein Purification
All chemicals were purchased from Sigma Chemical Co (St.
Louise, MO). The GAGs and polymers used were: porcine
intestinal heparin (grade I-A, molecular weight 18000 and
5000 Da), heparan sulfate (HS), chondroitin sulfate A, B and C
(ChonA, DS and ChonC), dextran and dextran sulfate, polylysine
(Mw 70000-15000) and polyarginine (Mw 15000-70000). Wild-
type and W7FW14F apomyoglobin were expressed and purified as
described previously [46]. Protein concentration was measured
under denaturing conditions by UV absorption using an e280 value
of 13,500 M
21 cm
21 for wild-type and an e275 value of
3750 M
21 cm
21 for W7FW14F apomyoglobin.
Fibril Formation
Aggregation of W7FW14F apomyoglobin was initiated by
raising the pH of a 40 mM protein solution from 4.0 to 7.0. This
results in the formation of protein aggregates in a prefibrillar form
that turn into mature fibrils in 7–15 days [48]. GAGs were added
to the protein solution both before the pH was raised to neutrality,
and immediately after. The effect of GAGs was identical in both
conditions.
Spectroscopic measurements
Absorption measurements were recorded at 25uC on a Jasco V-
550 double-beam spectrophotometer. The protein samples, at a
concentration of 40610
26 M, were centrifuged at 20000 g for
30 min and the absorbance at 280 nm of supernatant solution was
measured. A single-exponential function was fitted to the kinetic
plots of the measured absorbance versus time to determine the
apparent aggregation rate constants. The following equation was
used:
A280nm t ðÞ ~A280nm ? ðÞ zA1e{kt ð1Þ
where A280 nm(‘) is the limiting absorbance, A1 and K are the
amplitude and rate constant of the observed change, respectively.
Far UV circular dichroism (CD) spectra were recorded at 25uC
on a Jasco J-810 spectropolarimeter using thermostated quartz
cells of 0.1 cm. Spectra were acquired at 0.2-nm intervals with a
4 s integration time and a bandwidth of 1.0 nm. An average of
three scans was obtained for all spectra. Photomultiplier
absorbance did not exceed 600 V in the spectral region analyzed.
Data were corrected for buffer contributions and smoothed using
the software provided by the manufacturer (System Software
version 1.00). All measurements were performed under nitrogen
flow. The protein samples (40610
26 M) were diluted 1:2 before
spectra acquisition. The results were expressed as mean residue
ellipticity [H]MRW in units of degree cm
2 dmol
21.
Thioflavin T fluorescence measurements
The aggregation kinetics was monitored using the dye
Thioflavin T (ThT) that exhibits enhanced fluorescence upon
GAGs and Protein Aggregation
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carried out with a Perkin Elmer Life Sciences LS 55 spectroflu-
orimeter. Excitation and emission wavelengths were set at 450 and
482 nm, respectively. The excitation and emission slit widths were
set at 5 nm each. ThT stock solution was prepared in Tris buffer
(pH 8.0, 20 mM) at a concentration of 500 mM and stored at 4uC.
At different time intervals, aliquots of samples (40 mM), incubated
in the presence or in the absence of GAGs, were mixed (1:1 v/v)
with buffer containing ThT. The final ThT concentration was
50 mM. The fluorescence spectra were recorded and the
fluorescence intensity at 482 nm was corrected by subtracting
the emission intensity of ThT/GAGs solutions.
Fourier transform infrared measurements
Fourier Transform Infrared (FTIR) spectra were recorded on a
Multiscope FT-IR microscope coupled with a Spectrum One
spectrometer (PerkinElmer, Wellesley, MA, USA). The FTIR
spectra in transmission mode were collected (4000 cm
21-
600 cm
21 range) at a resolution of 4 cm
21 with 16 accumulations
per run. For each spectrum, signals corresponding to the water
and CO2 vapors were automatically subtracted and the baseline
corrected. Spectra were recorded with dry samples of protein
obtained from repeated cycles of lyophilization and dissolution in
D2O at a concentration of 40 mM.
Transmission electron microscopy
Fibril formation in the presence of heparin was monitored by
transmission electron microscopy (EFTEM Lybra 120, Zeiss,
Germany). Protein aliquots of 10 mL were sampled from a protein
solution of 40 mM, diluted 1:10 and deposited on 400-mesh
formvar-coated grid (Electron Microscopy Sciences, Hatfield, UK)
and allowed to absorb for about 1 min. The excess liquid was
removed with filter paper. A drop of negative stain (1% aqueous
uranyl acetate made up fresh (Laurylab, Saint-Fons Cedex,
France) was placed on the grid for 1 min and allowed to dry.
Cell culture and incubation with protein aggregates
NIH-3T3 cells (mouse fibroblasts, American Type Culture
Collection) were cultured in Dulbecco’s modified eagle’s medium
(DMEM)-high glucose supplemented with 10% bovine calf serum
and 3.0 mM glutamine in a 5.0% CO2 humidified environment at
37uC. 50 units/mL penicillin and 50 mg/mL streptomycin were
added to the medium. The cells were plated at a density of
100,000 cells/well on 12-well plates in 1 mL of medium. After
24 h, protein samples (40 mM) were mixed 1:1 v/v with cell media
and incubated. Cells in culture medium without protein served as
control.
MTT assay
Cell viability was assessed as the inhibition of the ability of cells
to reduce the metabolic dye 3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyltetrazolium bromide (MTT) to a blue formazan product
[49]. After 24 h of incubation with protein samples, cells were
rinsed with phosphate buffer solution (PBS). 100 mL of a stock
MTT solution (5 mg/mL in PBS) were then added to 900 mLo f
DMEM without phenol red containing 10% bovine calf serum/
well, and incubation was continued at 37uC for an additional 3 h.
The medium was aspirated, and cells were treated with isopropyl
alcohol-0.1 M HCl for 20 min. Levels of reduced MTT were
determined by measuring the difference in absorbance at 570 and
690 nm. Data are expressed as average percent reduction of MTT
with respect to the control 6 S.D. from five independent
experiments carried out in triplicate. For statistical analysis, we
used a two-tailed Student’s t test with unequal variance at a
significance level of 5% unless otherwise indicated.
Results
The effect of heparin on aggregation process of
W7FW14F apomyoglobin at pH 7.0
The effect of heparin as modulator of the amyloid aggregation
of the W7FW14F apomyoglobin mutant was explored using
absorbance, CD, FTIR, ThT fluorescence and EM measure-
ments. We previously showed that, similar to the wild-type protein,
the W7FW14F mutant is fully unfolded at pH 2.0 and partially
folded at a pH near 4.0. When pH is increased from 4.0 to 7.0, the
mutant protein aggregates and forms amyloid fibrils by a
characteristic nucleation-dependent polymerization mechanism,
whereas the wild-type protein folds correctly [47,48]. At the
beginning of the aggregation process, the aggregating protein
molecules have a native-like conformation with an abundant
alpha-helical content. These species assemble to form oligomeric
species that, between 12 and 24 h, give rise to amyloid-like
protofilaments. The latter develop slowly to form, after 5–6 days,
protofibrils that then associate further to form the higher order
amyloid fibrils. The early aggregates have the structural
characteristics of amyloid precursors, namely, the ability to bind
ThT and Congo red, and an extensive b-sheet structure [48,50].
We first studied the effect of heparin on the early stage of the
aggregation process by measuring the protein concentration of the
soluble fraction upon increasing the pH from 4.0 to 7.0. Heparin
was added to protein solution both immediately before and after
the pH was increased to neutrality. Protein samples were then
centrifuged at 20,000 g for 30 min to obtain a supernatant
prevalently containing soluble protein, and absorbance was
measured at 280 nm. Figure 1A shows the time-dependence of
W7FW14F apomyoglobin aggregation at pH 7.0 in the presence
and absence of heparin. The more rapid decrease of absorbance at
280 nm observed in the presence of heparin indicates that the
aggregation rate increased upon GAG addition. The aggregation
rates obtained by fitting the experimental data to a single
exponential function A280 nm(t)=A280 nm(‘)+A1 e
2kt (equation 1)
were: 0.01460.0035 min
21 and 0.05660.006 min
21 in the
absence and in the presence of heparin, respectively. Moreover,
the fraction of soluble protein was greatly reduced in the presence
of heparin, which suggests that heparin promoted the formation of
a higher amount of aggregates.
To gain further insight into the mechanism by which heparin
increased the aggregation rate of the amyloid-forming apomyo-
globin mutant, we analyzed the far-UV CD spectra as a function
of time. Circular dichroism spectra were recorded immediately
after pH neutralization of the protein samples (Figure 1B). During
the first 6 h of observation, in the absence of heparin (left), the
shape of the CD spectra did not change, all spectra showing the
two minima at 208 and 222 nm, which is characteristic of an a-
helical conformation, whereas the intensity of the CD signal
decreased gradually due to the increase of light scattering caused
by protein aggregation [50]. The CD spectrum was very different
in the presence of heparin (right). In fact, soon after the pH was
increased to neutrality, the minimum centered at 222 nm was still
evident whereas that at 208 nm was very faint and disappeared as
aggregation proceeded. The spectrum recorded after completion
of the fibril formation process of the W7FW14F apomyoglobin in
the absence of heparin is shown for comparison purposes.
We used FTIR spectroscopy, which is a very sensitive technique
widely used to monitor the a-to b-transition underlying amyloid
formation [51,52], to obtain direct information about the structure
GAGs and Protein Aggregation
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heparin. Figure 2 shows the spectra recorded soon after the onset
of the aggregation reaction performed with and without heparin.
The spectrum recorded in the absence of heparin shows an amide
I’ at 1659 cm
21, which indicates that the first aggregates formed
contain a considerable amount of a-helical conformation, and that
the beta transition has not yet occurred [50]. Conversely, the
spectrum recorded in the presence of heparin has an amide I’
maximum close to 1625 cm
21. This value is typical of an amyloid
conformation [53] and is similar to that found for the amide I’ of
amyloid fibrils formed by apomyoglobin [50,52].
We used ThT fluorescence to follow the time course of fibril
formation. This dye forms a complex with the cross-b structure
and its fluorescence intensity increases proportional to the amount
of fibrils present when the ThT concentration is held constant
[54,55]. As shown in Figure 3A, in the absence of heparin, ThT
fluorescence exhibited a sigmoidal time course, with a lag phase of
approximately 4 days, as reported previously [48]. Heparin
dramatically accelerated the amyloid aggregation process. In fact,
it caused an instantaneous increase in ThT fluorescence intensity
thereby determining loss of the lag-phase in the amyloid fibril
formation kinetics. Moreover, the plateau fluorescence value was
much higher with than without heparin. The addition of salts
(200 mM NaCl) to protein samples incubated with heparin
resulted in an aggregation kinetics superimposable to that
observed in the absence of heparin (data not shown), thus
suggesting that the heparin-induced acceleration of W7FW14F
apomyoglobin aggregation is due largely to electrostatic interac-
tions between the two oppositely charged molecules.
Using electron microscopy, we next examined the morphology
of the W7FW14F apomyoglobin aggregates obtained in the
absence and presence of heparin at the onset of aggregation
Figure 1. Effect of heparin on the early stage of the aggregation process of W7FW14F apomyoglobin at pH 7.0. Panel A: Aggregation
was monitored by measuring the absorbance at 280 nm of supernatant solution after centrifugation in the absence (&) and in the presence of
0.1 mg/mL heparin (N). Protein concentration was 40 mM. Points are experimental values, continuous lines were obtained from an exponential fit as
A280 nm(t)=A280 nm(‘)+A1 e
2kt. Panel B: Time-dependence of the far-UV CD spectra in the absence (left) and in the presence (right) of 0.1 mg/mL
heparin. From the lower to the upper spectrum, times are: 1, 5, 20, 120, 240, and 360 min. The protein samples (40 mM) were diluted 1:2 before
spectra acquisition. In red is displayed the spectrum recorded at the end of fibrillation process in the absence of heparin.
doi:10.1371/journal.pone.0022076.g001
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the absence of heparin, whereas protofibrils were found in the
heparin-treated sample. Consistent with FTIR spectra and ThT
staining, the electron microscope images show that the formation
of fibrillar species is accelerated in the presence of heparin.
However, the EM images recorded 2–4 days after the onset of
aggregation revealed that the fibrillar species obtained in the
presence of heparin are branched and thicker than mature fibrils
of control protein at the end of aggregation process (Figure 3C).
The same picture was obtained at longer times.
We also evaluated whether the fibrillation kinetics was related to
heparin concentration to understand better the effect of heparin
on the lag phase. The addition of increasing concentrations of
heparin led to a reduction of the lag and a progressive increase in
the magnitude of the fluorescence plateau value (Figure 4). The
dependence of the transition midpoint on the heparin/apomyo-
globin molar ratio (inset of figure) indicates that the number of
W7FW14F apomyoglobin molecules per heparin molecule varies
from 40 to 5 on increasing polyanion concentration. In summary,
incubation of W7FW14F apomyoglobin with heparin resulted in a
substantial acceleration of the aggregation and fibrillation
processes, and the magnitude of the acceleration effect was related
to GAG concentration.
The effect of heparin on the aggregation process of
W7FW14F apomyoglobin at pH 4.0
To probe further the mechanism by which heparin induced
amyloid formation, we investigated its effect on the partially folded
soluble conformation that W7FW14F apomyoglobin adopts near
pH 4.0 [47]. Under this condition, the addition of heparin caused
aggregation(Figure5A)witha kinetics ratefasterthan that observed
at pH 7.0, i.e., 0.09660.015 min
21 vs. 0.05660.006 min
21. The
CD spectra recorded during the first 6 h of the process (Figure 5B)
revealed the presence of two distinct successive conformational
populations. The first appeared soon after the addition of heparin
(20, 40, 60, and 120 min), whereas the second appeared much later
(3, 5, and 6 h). It is interesting to note that the CD spectra obtained
soon after the addition of heparin at pH 4.0 are similar, if not
identical,tothoserecordedatneutralpHinthepresenceofheparin,
whereasthe spectraobtained atlongertimesarepracticallyidentical
with that of mature fibrils (Figure 1B). FTIR analysis revealed that
the amide I’ maximum of both forms is close to 1625 cm
21 (data
not shown), which supports the concept that the aggregated protein
is essentially b-structured. Moreover, the heparin-induced aggre-
gatesformedat pH 4.0werealso able tobindThT(Figure5C). The
intensity of ThT fluorescence measured soon after heparin addition
was three-fold higher than that detected at pH 7.0 in the absence of
heparin, which indicates that the aggregates have a prevalently
cross-b structure, consistent with FTIR analysis. The initial
instantaneous appearance of ThT fluorescence was followed by
further increases and reached maximum value 5 days after the
addition of heparin.
To examine the effect of heparin on fully unfolded apoprotein,
we carried out the same experiments at pH 2.0 in the presence of
heparin. The results were superimposable to those obtained at
pH 4.0 thereby showing that heparin is also able to induce
aggregation of unfolded apomyoglobin (data not shown).
The cytotoxicity of heparin-induced W7FW14F
apomyoglobin aggregates
We assessed the cytotoxicity of W7FW14F apomyoglobin
aggregates obtained in the presence of heparin using the MTT
assay, which is a rapid and sensitive indicator of amyloid-mediated
toxicity. The toxicity of amyloid aggregates is closely linked to the
presence of oligomeric species; in fact, decreased levels of MTT
reduction are usually detected in the presence of soluble
prefibrillar oligomers but not of fibrils [48,56–60]. We compared
the toxicity of aggregates formed in the absence and presence of
heparin at aggregation onset and 7 and 15 days thereafter, at both
pH 4.0 and pH 7.0. As expected, in the absence of heparin, early
prefibrillar aggregates were toxic (about 45% MTT reduction),
whereas fibrillar aggregates (at 7 and 15 days) were not (Figure 6)
in accordance with a previous study [48]. The aggregates formed
by the protein in the presence of heparin, at both pH 7.0 and 4.0,
did not affect cell viability even at the beginning of the aggregation
process. The lack of cytotoxicity well correlates with our finding
that heparin induces rapid formation of harmless fibrillar
aggregates.
The effect of heparin on wild-type apomyoglobin
The addition of heparin to native wild-type apomyoglobin
caused protein aggregation (Figure 7). The rate of aggregation
depended on pH in the range 5.5–7.0, at which the protein retains
its native fold. At neutral pH, heparin induced only a slight
turbidity, whereas massive precipitation was observed at lower pH
values. Figure 7A shows the time course of protein aggregation
measured at pH 7.0 and 5.5 in the first hour after the addition of
heparin. At pH 5.5, the fraction of precipitated apomyoglobin was
much higher than that measured at pH 7.0 (88% versus,10%).
The time course of protein aggregation at pH 5.5 was not affected
by 200 mM NaCl.
Figure 7B shows the effect of increasing heparin concentration
on the CD spectrum of wild-type apomyoglobin at neutral pH.
Heparin progressively reduced the intensity of the signal, which
reached a plateau at a concentration as high as 0.1 mg/mL (inset
of Figure 7B). Next, we examined the time-dependence of the CD
spectrum of wild-type apomyoglobin in the presence of 0.1 mg/
Figure 2. FTIR spectra in the amide I’ region of amyloid-
forming W7FW14F apomyoglobin at pH 7.0. The spectra have
been recorded at the beginning of the aggregation process in the
absence (black line) and in the presence (gray line) of 0.1 mg/mL
heparin.
doi:10.1371/journal.pone.0022076.g002
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drastically changed upon the addition of heparin, and remained
stable for 1 h thereafter. Major changes were observed after 24
and 48 h. In particular, the CD spectrum recorded at pH 5.5 48 h
after heparin addition was very similar, if not identical, to that
recorded upon completion of the fibrillation process of the
amyloid-forming mutant in the absence of heparin. The secondary
structure content of the species appearing at different times and
pH values was estimated and the results are reported in Table 1.
It is feasible that the above results are related to the extent of
histidine protonation that occurs in the pH range examined. As
pH decreases, the net positive charge of the protein molecule
increases, thereby favoring interactions with the negatively
charged groups of heparin. The interaction between heparin
and apomyoglobin is also responsible for the occurrence of
conformational changes revealed by the extensive variation of the
shape of CD spectra and by the related CD analysis of secondary
structure shown in Table 1.
We monitored the structural evolution of the aggregates using
FTIR spectroscopy, ThT fluorescence and electron microscopy.
The FTIR spectra of the wild-type apomyoglobin at pH 5.5 in the
presence of heparin recorded 2 days after the onset of aggregation
showed an amide I’ maximum close to 1625 cm
21 (data not
shown), which indicates the presence of the cross-b structure. The
ThT fluorescence confirmed this result. As expected, in the
absence of heparin, fluorescence did not increase at either pH 7.0
or pH 5.5. Conversely, ThT reactive aggregates were readily
formed in the presence of heparin (Figure 8A). Electron
microscopy showed the presence of fibrillar structures
(Figure 8B). Figure 8C shows the effect of the heparin-induced
wild-type apomyoglobin aggregates on cell viability. Aggregates
were added to the cultured cells at various times after aggregation
onset. The protein aggregates formed at the start of aggregation at
pH 7.0 killed about 60% of cells, whereas the aggregates formed at
pH 5.5 were harmless. Six days after aggregation onset, the
aggregates formed at both pH values were not cytotoxic. The
Figure 3. Effect of heparin on the fibrillogenesis process of W7FW14F apomyoglobin at pH 7.0. Panel A: ThT fluorescence in the
absence (&) and in the presence (N) of 0.1 mg/mL heparin. Protein concentration was 40 mM. Other experimental details are described in Materials
and Methods. Panel B: Electron microscope images of W7FW14F apomyoglobin in the absence of heparin at the beginning (1) and at the end of the
aggregation process (3), and in the presence of heparin at the beginning of the aggregation process (2) and 2–4 days thereafter (4).
doi:10.1371/journal.pone.0022076.g003
GAGs and Protein Aggregation
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aggregation at pH 7.0 and pH 5.5 could be related to their
different compactness. At pH 7.0, the low number of electrostatic
interaction between heparin and protonated hystidyl residues
makes the aggregates less compact thereby determining an
increase of their exposed hydrophobic area [61]. This different
toxicity could also be due to the acceleration of the heparin-
induced aggregation that occurs at pH 5.5 (Figure 7A). In fact, it
could well be that under these conditions, a reduced steady-state
level of early toxic aggregates is reached consequent to the
increased rate of oligomer growth into harmless higher order
assemblies, as recently reported for TTR aggregation in the
presence of heparin [46].
Taken together, the results we obtained with wild-type
apomyoglobin indicate that heparin is able to induce an amyloid
aggregation process that readily terminates with the formation of a
fibrillar species rich in cross-b structure.
Effect of different glycosaminoglycans and polymers on
aggregation kinetics
The magnitude of the effect of GAGs on amyloid aggregation
depends on the GAG used [25,29]. Therefore, we examined the
effect of different GAGs and polymers on W7FW14F apomyoglo-
bin fibril formation. As shown in Figure 9, similar to heparin, both
heparan sulfate and lower molecular weight heparin greatly
increased the yield and rate of fibril formation. Chondroitin sulfate
A increased the yield and rate of fibril formation to a much lesser
extent, whereas chondroitin sulfate B and C did not have any
effect. We also examined the effect of a charged polymer, dextran
sulfate, and found that it had, reproducibly, an effect similar to
that of heparin. Therefore, also dextran sulfate accelerated
amyloid fibril formation, which suggests that the presence of
negative charges promotes amyloid fibril formation. To determine
if the enhancing effect of dextran sulfate is due to the sulfates, we
tested dextran, and found it had no effect. Therefore, the presence
of negatively charged groups seems to be essential for the
stimulatory effect exerted by charged polymers on the
W7FW14F apomyoglobin mutant. As negative control, we tested
the effect of the positively charged polyelectrolytes polylysine and
polyarginine. Unlike polyanions that promoted the aggregation of
positively charged proteins, the polycations did not affect the
aggregation process.
Discussion
It is generally agreed that amyloid fibril formation results from a
nucleation and growth process and that the presence of a lag phase
Figure 4. Effect of heparin concentration on W7FW14F apomyoglobin fibrillation kinetics. Fibrillization was monitored by the increase in
fluorescence of ThT, as described under Materials and Methods. Protein concentration was 40 mM. Heparin concentrations were 0.1 (#), 0.06 (%),
0.015 (¤), 0.010 (m), 0.003 (&), and 0 mg/mL (N).The inset shows the dependence of the transition midpoint on heparin/apomyoglobin molar ratio.
doi:10.1371/journal.pone.0022076.g004
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genic W7FW14F apomyoglobin forms fibrils in not less than 9–10
days after a lag-phase lasting 4–5 days [48]. We found that, in the
presence of heparin, mutant apomyoglobin forms branched and
thicker fibrils within 2–4 days of the start of the aggregation
process. This is mainly due to the electrostatic interaction between
the positively charged side chains of apomyoglobin and the
negatively charged regions of heparin that leads to the formation
of protein-GAG complexes. This interaction may partially mask
the charge–charge repulsion between the neighboring apomyo-
globin molecules thereby determining a considerable increase in
the local concentration of protein, which is a factor favoring rapid
fibrillation [25]. Our experimental observation that heparin-
induced acceleration of fibril formation is overturned when salts
are added lends weight to this concept.
Given the strong dependence of lag phase on heparin
concentration (Figure 4), we postulate that heparin templates the
monomers or oligomers to associate thereby reducing the lag
phase of the W7FW14F apomyoglobin fibrillization process. This
hypothesis is substantiated by the finding that at the highest
heparin concentration used, the aggregation rate in the early stage
of the process was four-times higher than that observed in the
absence of heparin, and the fraction of soluble protein was strongly
reduced (Figure 1). Taken together, these results suggest that
heparin promotes the formation of a higher concentration of
nuclei starting from monomeric soluble species and/or oligomeric
aggregates.
The FTIR spectra recorded soon after aggregation onset were
consistent with rapid formation of cross-b rich nuclei acting as
seeds for fibril formation. This conclusion corroborates the
concept that heparin provides a spatially organized network that
Figure 5. Effect of heparin on W7FW14F apomyoglobin at pH 4.0. Panel A: Absorbance at 280 nm of supernatant solution in the absence
(&) and in the presence of 0.1 mg/mL heparin (N). Protein concentration was 40 mM. Points are experimental values, continues line was obtained
from an exponential fit as A280 nm(t)=A280 nm(‘)+A1 e
2kt. Panel B: Time-dependence of the far-UV CD spectra in the presence of 0.1 mg/mL heparin.
From the lower to the upper spectrum, times are: 20, 40, 60, 120, 180, 300 and 360 min. The protein samples (40 mM) were diluted 1:2 before spectra
acquisition. In red is displayed the spectrum recorded in the absence of heparin. Panel C: ThT fluorescence in the absence (&) and in the presence of
0.1 mg/mL heparin (N). Protein concentration was 40 mM. Other experimental details are reported under ‘‘Materials and Methods’’.
doi:10.1371/journal.pone.0022076.g005
Figure 6. Effect of W7FW14F apomyoglobin aggregates on cell
viability detected by MTT assay. NIH-3T3 cells were exposed to
aggregates formed in the absence (dark grey) and in the presence of
0.1 mg/mL heparin at pH 7.0 (light grey) and at pH 4.0 (white). Aliquots
of protein were taken at 0, 7, and 15 days from the onset of
fibrillogenesis and incubated for 24 h with cells. Data are expressed as
average percentage of MTT reduction 6 SD relative to cells treated with
medium alone or medium plus heparin, from triplicate wells from 5
separate experiments. Other experimental details are reported under
‘‘Materials and Methods’’. Only early aggregates formed in the absence
of heparin caused a significant decreases in reduced MTT levels
(P,0.01).
doi:10.1371/journal.pone.0022076.g006
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with each other [14,62]. In this context, it is noteworthy that, at a
low heparin concentration, 40 apomyoglobin molecules are bound
to each heparin molecule (Figure 4, inset). The large molar excess
of protein over heparin could also be indicative of the binding of
heparin to oligomeric, rather than to monomeric forms of
apomyoglobin. At increasing heparin concentrations, the ratio of
apomyoglobin to heparin decreases from 40 to 5, which is
consistent with the possibility that heparin binds monomeric
instead of oligomeric forms of apomyoglobin. However, we can
not exclude that, at the highest concentration used, heparin might
induce conformational changes leading to a more extended,
ordered spatial orientation of protein molecules in the early
formed aggregated complexes. The binding of heparin to amyloid
proteins has been reported to increase the degree of order of the
protein within the aggregates, thus favoring the fibrillation process
[32].
In a variety of proteins that are induced to form b-structure,
heparin binding sites have been shown to contain clusters of basic
amino acid residues capable of binding to the negatively charged
heparin molecules [63–66]. In particular, Cardin and Weintraub
[63] reported that heparin binding domains usually contain the
consensus sequences XBBBXXBX or XBBXBX, where B is a basic
amino acid and X is a non basic amino acid in both the alpha-
helical and beta-strand conformation. Apomyoglobin contains
three consensus sequences corresponding to the above-indicated
sequences, localized in the turn regions between helices C–D, E–F,
and F–G. Moreover, clusters of basic amino acids that do not
conform to the sequences identified by Cardin and Weintraub are
present in the primary structure at the end of the B helix, i.e.,
Figure 7. Effect of heparin on wild-type apomyoglobin at pH 7.0 and 5.5. Panel A: Absorbance at 280 nm of supernatant solution in the
presence of 0.1 mg/mL heparin at pH 7.0 (&) and at pH 5.5 (¤). Protein concentration was 40 mM. Points are experimental values, continues lines
were obtained from an exponential fit as A280 nm(t)=A280 nm(‘)+A1 e
2kt. Panel B: Effect of increasing concentration of heparin on the far-UV CD
spectra of protein at pH 7.0. From the lower to the upper spectrum, heparin concentrations were: 0, 0.01, 0.025, 0.05, 0.075, 0.1 and 0.2 mg/mL. The
protein samples (40 mM) were diluted 1:2 before spectra acquisition. The inset shows the dependence of the molar ellepticity at 208 nm on heparin
concentration. Panel C: Time-dependence of CD spectra in the presence of 0.1 mg/mL of heparin at pH 7.0 (left) and pH 5.5 (right). The lower
spectra are those of protein in the absence of heparin.
doi:10.1371/journal.pone.0022076.g007
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end of the G-helix, i.e., HVLHSRH (Figure 10). We propose that
the crucial step of heparin-induced fibrillation is the recognition
and binding to the basic cluster sequences localized on turn
regions of the protein that are easily accessible. The observation
that heparin induces amyloid aggregation of both partially folded
and fully unfolded apoprotein suggests that the basic binding
sequences are not necessarily located in helical structured regions.
Heparin can, therefore, act as an immobilizing charged surface on
which protein monomers are correctly oriented for priming an
ordered polymerization that generates fibril seeds. It is also
possible, as documented by our FTIR analysis, that heparin
directly promotes the a-to-b structural transitions within mono-
meric species of the W7FW14F apomyoglobin mutant and so lead
to acceleration of aggregation and fibril formation. At present, it is
difficult to determine whether heparin simply acts as a
concentrating surface on which protein molecules become in close
contact or whether it induces conformational transitions as a
consequence of which the formation of cross-b structure is favored.
Probably, both effects are responsible for the observed acceleration
Table 1. Secondary structure percent content of wild-type
apomyoglobin at various pHs and heparin incubation times.
pH Time Hep* abTurn Random
7.0 0 2 0.58 0.06 0.13 0.23
7.0 25 min + 0.34 0.16 0.20 0.30
7.0 24 h + 0.27 0.22 0.21 0.30
7.0 48 h + 0.08 0.36 0.22 0.34
5.5 25 min + 0.20 0.37 0.20 0.23
5.5 24 h + 0.05 0.45 0.22 0.28
5.5 48 h + 0.05 0.45 0.21 0.29
6.0 25 min + 0.35 0.17 0.20 0.28
*Heparin: 0.1 mg/mL.
doi:10.1371/journal.pone.0022076.t001
Figure 8. Effect of heparin on wild-type apomyoglobin amyloid aggregation and cytotoxic activity. Panel A: ThT fluorescence in the
absence (¤) and in the presence of 0.1 mg/mL heparin at pH 5.5 (m) and at pH 7.0 (&). Protein concentration was 40 mM. Other experimental
details are reported in Materials and methods. Panel B: Electron microscopy image of the protein in the presence of 0.1 mg/mL heparin at the
beginning of the aggregationprocess. Panel C: Cell viability of NIH-3T3 cellsexposed to wild-typeapomyoglobinaggregates formed in the presence of
0.1 mg/mL heparin at pH 7.0 (grey) and at pH 5.5 (white) detected by MTT assay. Aliquots of protein were taken at 0, and 6 days from the onset of the
aggregation process and incubated for 24 h with cells. Data are expressed as average percentage of MTT reduction 6 SD relative to cells treated with
medium plus heparin, from triplicate wells from 5 separate experiments. Other experimental details are reported under ‘‘Materials and Methods’’.
doi:10.1371/journal.pone.0022076.g008
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heparin induces a pathway of aggregation different from that of
the amyloidogenic apomyoglobin in experimental conditions
similar to the physiological setting.
The proposed mechanism for the heparin-induced aggregation
and fibrillation of the W7FW14F mutant under aggregating, i.e.,
pH 7.0, and non-aggregating experimental conditions, i.e., at
pH 4.0 and 2.0, is supported by the results obtained with the wild-
type apomyoglobin, a protein that does not undergo aggregation
and fibril formation under native conditions. In fact, we found that
the addition of heparin to this protein caused aggregation and
fibril formation that was much more evident on lowering the pH
from 7.0 to 5.5. The increased susceptibility to aggregation after
pH lowering could be due to histidine protonation, which
increases the net positive charge of the apomyoglobin thereby
favoring the heparin-protein interaction. However, it can not be
excluded that pH affects protein stability. It has been shown that
lowering pH from 7.0 to 5.5 reduces the conformational stability
by about 2–3 kcal/mole thereby making the protein more
susceptible to perturbing agents [67,68]. The observation that
the addition of salt at pH 5.5 does not influence the heparin-
induced aggregation profile indicates that the increased aggrega-
tion is not only related to histidine protonation but also to a
greater propensity of the protein to undergo structural modifica-
tions. In this context, the proton gradient formed in proximity of
the heparin surface is likely to modify the structural properties of
the protein and possibly favor its misfolding.
We also show that the effect on W7FW14F apomyoglobin fibril
formation varies depending on the polymer used. A similar
variability has been reported for other amyloidogenic proteins. In
the case of a-synuclein, heparin and dextran sulfate had a stronger
effect than polyglutamic acid, chondroitin-4-sulfate and dermatan
sulfate, whereas chondroitin-6-sulfate and inhibition by dextrane
had little or no effect [29]. Our results with mutant apomyoglobin
show that acceleration of fibril formation depends on the
polyanionic character of a GAG. In fact, neutral compounds such
as dextran or positively charged compounds such as polylysine or
polyarginine did not stimulate fibril formation.
Figure 10. Consensus sequences for heparin binding along the helices in apomyoglobin structure. Each of the 8 alpha-helices is marked
with a letter and is represented by an ellipsoid of size proportional to the length of the sequence. Residues corresponding to Cardin and Weintraub
motifs are boxed. Basic residues are shown in red.
doi:10.1371/journal.pone.0022076.g010
Figure 9. Effect of different GAGs on fibrillogenesis process of
W7FW14F apomyoglobin at pH 7.0 monitored by ThT fluores-
cence. (e) absence of GAGs; (N) 0.1 mg/mL heparin; (x) 0.1 mg/mL
heparan sulfate; (m) 1 mg/mL dextran sulfate; (2) 1 mg/mL condroitin
A; (&) 0.1 mg/mL low molecular weight heparin; (+) 1 mg/mL
condroitin B; (*) 0.6 mg/mL polyarginine; (%) 1 mg/mL condroitin C;
(#) 0.7 mg/mL dextran; (D) 0.6 mg/mL polylysine.
doi:10.1371/journal.pone.0022076.g009
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therapeutic implications because it induces the protein to assume a
non-toxic fibrillar conformation. Increasing aggregation rates
reduce the lag time for fibril formation, thereby reducing the
time of exposure to toxic intermediates that cause cell death. In
fact, we show that the protein is harmless when incubated with
heparin. The most interesting aspect of our study is that heparin
induced amyloid formation of natively folded wild-type apomyo-
globin, which normally does not show any tendency to aggregate.
Thus, heparin could play a dual role in amyloidosis, as a safe
compound and as a pathological chaperone. The question is
whether GAGs can be used as a therapeutic target in patients
affected by amyloid-associated diseases or whether they are
deleterious to health because they increase the fibril load. In fact,
promoting formation of intracellular amyloid inclusions in
Parkinson’s and Huntington’s disease may protect against
pathological damage [69,70] or may enhance oxidative stress by
promoting cell death [71].
Author Contributions
Conceived and designed the experiments: IS GI. Performed the
experiments: SV RS RM AD. Analyzed the data: SV RS RM. Contributed
reagents/materials/analysis tools: SV RS RM. Wrote the paper: IS GI.
References
1. Chiti F, Dobson C (2006) Protein misfolding, functional amyloid, and human
disease. Annu Rev Biochem 75: 333–366.
2. Makin OS, Serpell LC (2002) Examining the structure of the mature amyloid
fibril. Biochem Soc Trans 30: 521–525.
3. Sipe JD, Cohen AS (2000) Review: History of the amyloid fibril. J Struc Bio 130:
88–98.
4. Nelson R, Sawaya MR, Balbirnie M, Madsen AO, Riekel C, et al. (2005)
Structure of the cross-beta spine of amyloid fibrils. Nature 435: 773–778.
5. Harper JD, Lansbury PT, Jr. (1997) Models of amyloid seeding in Alzheimer’s
disease and scrapie: Mechanistic truths and physiological consequences of the
time-dependent solubility of amyloid proteins. Annu Rev Biochem 66: 385–407.
6. Bucciantini M, Giannoni E, Chiti F, Baroni F, Formigli L, et al. (2002) Inherent
toxicity of aggregates implies a common mechanism for protein misfolding
diseases. Nature 416: 507–511.
7. Kayed R, Head E, Thompson JL, McIntire TM, Milton SC, et al. (2003)
Common structure of soluble amyloid oligomers implies common mechanism of
pathogenesis. Science 300: 486–489.
8. Lashuel HA, Hartley D, Petre BM, Walz T, Lansbury PTJ (2002) Amyloid pores
from pathogenic mutations. Nature 418: 291.
9. Ehrnhoefer DE, Bieschke J, Boeddrich A, Herbst M, Masino L, et al. (2008)
EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway
oligomers. Nat Struct Mol Biol 15: 558–566.
10. Masuda M, Suzuki N, Taniguchi S, Oikawa T, Nonaka T, et al. (2006) Small
molecule inhibitors of a-synuclein filament assembly. Biochemistry 45:
6085–6094.
11. Bodner RA, Housman DE, Kazantsev AG (2006a) New directions for
neurodegenerative disease therapy—using chemical compounds to boost the
formation of mutant protein inclusions. Cell Cycle 5: 1477–1480.
12. Bodner RA, Outeiro TF, Altmann S, Maxwell MM, Cho SH, et al. (2006b)
Pharmacological promotion of inclusion formation: a therapeutic approach for
Huntington’s and Parkinson’s diseases. Proc Natl Acad Sci USA 103:
4246–4251.
13. Kvam E, Nannenga BL, Wang MS, Jia Z, Sierks MR, et al. (2009)
Conformational targeting of fibrillar polyglutamine proteins in live cells escalates
aggregation and cytotoxicity. PLoS ONE 4: e5727.
14. Bellotti V, Chiti F (2008) Amyloidogenesis in its biological environment:
challenging a fundamental issue in protein misfolding diseases. Curr Opin Struct
Biol 18: 771–779.
15. Bosman FT, Stamenkovic I (2003) Functional structure and composition of the
extracellular matrix. J Pathol 200: 423–428.
16. Alexandrescu AT (2005) Amyloid accomplices and enforcers. Protein Sci 14:
1–12.
17. van Horssen J, Wesseling P, van den Heuvel LP, de Waal RM, Verbeek MM
(2003) Heparan sulphate proteoglycans in Alzheimer’s disease and amyloid-
related disorders. Lancet Neurol 2: 482–492.
18. Diaz-Nido J, Wandossel F, Avila J (2002) Glycosaminoglycans and beta-amyloid,
prion and tau peptides in neurodegenerative duiseases. Peptides 23: 1323–1332.
19. Ancsin JB (2003) Amyloidogenesis: historical and modern observations point to
heparin sulfate proteoglycans as a major culprit. Amyloid 10: 67–79.
20. Cortijo-Arellano M, Ponce J, Durany N, Cladera J (2008) Amyloidogenic
properties of the prion protein fragment PrP(185–208): comparison with
Alzheimer’s peptide Abeta(1–28), influence of heparin and cell toxicity. Biochem
Biophys Res Commun 368(2): 238–42.
21. Snow AD, Kisilevsky R (1985) Temporal relationship between glycosaminogly-
can accumulation and amyloid deposition during experimental amyloidosis. A
histochemical study. Lab Invest 53: 37–44.
22. Kisilevsky R, Szarek WA, Ancsin JB, Elimova E, Marone S, et al. (2004)
Inhibition of amyloid A amyloidogenesis in vivo and in tissue culture by 4-deoxy
analogues of peracetylated 2-acetamido-2- deoxy-a- and b-D-glucose: Implica-
tions for the treatment of various amyloidoses. Am J Pathol 164: 2127–2137.
23. Elimova E, Kisilevsky R, Szarek WA, Ancsin JB (2004) Amyloidogenesis
recapitulated in cell culture: a peptide inhibitor provides direct evidence for the
role of heparan sulfate and suggests a new treatment strategy. FASEB J 18(14):
1749–51.
24. Li JP, Galvis ML, Gong F, Zhang X, Zcharia E, et al. (2005) In vivo
fragmentation of heparan sulfate by heparanase overexpression renders mice
resistant to amyloid protein A amyloidosis. Proc Nat Acad Sci 102: 6473–6477.
25. Castillo GM, Lukito W, Wight TN, Snow AD (1999) The sulfate moieties of
glycosaminoglycans are critical for the enhancement of beta-amyloid protein
fibril formation. J Neurochem 72: 1681–1687.
26. Castillo GM, Ngo C, Cummings J, Wight TN, Snow AD (1997) Perlecan binds
to the beta-amyloid proteins (A beta) of Alzheimer’s disease, accelerates A beta
fibril formation, and maintains A beta fibril stability. J Neurochem 69:
2452–2465.
27. McLaurin J, Franklin T, Zhang X, Deng J, Fraser PE (1999) Interactions of
Alzheimer amyloid-beta peptides with glycosaminoglycans: effects on fibril
nucleation and growth. Eur J Biochem 266: 1101–1110.
28. Goedert M, Jakes R, Spillantini MG, Hasegawa M, Smith MJ, et al. (1996)
Assembly of microtubule-associated protein tau into Alzheimer-like filaments
induced by sulphated glycosaminoglycans. Nature 383(6600): 550–553.
29. Cohlberg JA, Li J, Uverskky VN, Fink AL (2002) Heparin and other
glycosaminoglycans stimulate the formation of amyloid fibrils from a-synuclein
in vitro. Biochemistry 41: 1502–1511.
30. Suk JY, Zhang F, Balch WE, Linhardt RJ, Kelly JF (2006) Heparin accelerates
gelsolyn amyloidogenesis. Biochemistry 45: 2234–2242.
31. Relini A, De Stefano S, Torrassa S, Cavalleri O, Rolandi R, et al. (2008)
Heparin strongly enhances the formation of b2-microglobulin amyloid fibrils in
the presence of type I collagen. J B C 283(8): 4912–4920.
32. Calamai M, Kumita JR, Mifsud J, Parrini C, Ramazzotti M, et al. (2006) Nature
and significance of the interactions between amyloid fibrils and biological
polyelectrolytes. Biochemistry 45: 12806–12815.
33. Motamedi-Shad N, Monsellier E, Chiti F (2009) Amyloid formation by the
model protein muscle acylphosphatase is accelerated by heparin and heparin
sulfate through a scaffolding-based mechanism. J Biochem 146(6): 805–14.
34. Madine J, Middleton DA (2010) Comparison of aggregation enhancement and
inhibition as strategies for reducing the cytotoxicity of the aortic amyloid
polypeptide medin. Eur Biophys J 39(9): 1281–8.
35. Wong C, Xiong LW, Horiuchi M, Raymond L, Wehrly K, et al. (2001) Sulfated
glycans and elevated temperature stimulate PrP(Sc)-dependent cell-free
formation of protease-resistant prion protein. Embo J 20(3): 377–386.
36. Narindrasorasak S, Lowery D, Gonzalez-DeWhitt P, Poorman RA,
Greenberg B, et al. (1991) High affinity interactions between the Alzheimer’s
beta-amyloid precursor proteins and the basement membrane form of heparan
sulfate proteoglycan. J Biol Chem 266: 12878–12883.
37. Brunden KR, Richter-Cook NJ, Chaturvedi N, Frederickson RC (1993) pH
dependent binding of synthetic beta-amyloid peptides to glycosaminoglycans.
J Neurochem 61: 2147–2154.
38. Caughey B, Brown K, Raymond GJ, Katzenstein GE, Thresher W (1994)
Binding of the protease-sensitive form of PrP (prion protein) to sulfated
glycosaminoglycan and congo red. J Virol 68: 2135–2141.
39. Warner RG, Hundt C, Weiss S, Turnbull JE (2002) Identification of the heparan
sulfate binding sites in the cellular prion protein. J Biol Chem 277:
18421–18430.
40. Park K, Verchere CB (2001) Identification of a heparin binding domain in the
Nterminal cleavage site of pro-islet amyloid polypeptide. Implications for islet
amyloid formation. J Biol Chem 276: 16611–16616.
41. Ohashi K, Kisilevsky R, Yanagishita M (2002) Affinity binding of glycosami-
noglycans with beta(2)-microglobulin. Nephron 90: 158–168.
42. Heegaard NH, Roepstorff P, Melberg SG, Nissen MH (2002) Cleaved beta 2-
microglobulin partially attains a conformation that has amyloidogenic features.
J Biol Chem 277: 11184–11189.
43. Elimova E, Kisilevsky R, Ancsin JB (2009) Heparan sulphate promotes the
aggregation of HDL-associated serum amyloid A: evidence for a proamyloido-
genic histidine molecular switch. FASEB J 23: 3436–2448.
44. Zhu M, Souillac PO, Ionesco-Zanetti C, Carter SA, Fink AL (2002) Surface-
catalyzed amyloid fibril formation. J Biol Chem 277: 50914–50922.
45. Motamedi-Shad N, Monsellier E, Torrassa S, Relini A, Chiti F (2009) Kinetic
analysis of amyloid formation in the presence of heparin sulfate. Faster unfolding
and change of pathway. J Biol Chem 284(43): 29921–34.
GAGs and Protein Aggregation
PLoS ONE | www.plosone.org 12 July 2011 | Volume 6 | Issue 7 | e2207646. Bourgault S, Solomon JP, Reixach N, Kelly JW (2011) Sulfated glycosamino-
glycans accelerate transthyretin amyloidogenesis by quaternary structural
conversion. Biochemistry 50: 1001–1015.
47. Sirangelo I, Malmo C, Casillo M, Mezzogiorno A, Papa M, et al. (2002)
Tryptophanyl substitution in apomyoglobin determine protein aggregation and
amyloid-like fibril formation at physiological pH. J Biol Chem 277:
45887–45891.
48. Sirangelo I, Malmo C, Iannuzzi C, Mezzogiorno A, Bianco MR, et al. (2004)
Fibrillogenesis and cytotoxic activity of the amyloid-forming apomyoglobin
mutant W7FW14F. J Biol Chem 279: 13183–13189.
49. Hansen MB, Nielsen SE, Berg K (1989) Re-examination and further
development of a precise and rapid dye method for measuring cell growth/
cell kill. J Immunol Methods 119: 203–210.
50. Iannuzzi C, Vilasi S, Portaccio M, Irace G, Sirangelo I (2007) Heme binding
inhibits the fibrillization of amyloidogenic apomyoglobin and determines lack of
aggregate cytotoxicity. Protein Sci 16(3): 507–516.
51. Dzwolak W, Ravindra R, Lendermann J, Winter R (2003) Aggregation of
bovine insulin probed by DSC/PPC calorimetry and FTIR spectroscopy.
Biochemistry 42: 11347–11355.
52. Fandrich M, Forge V, Buder K, Kittler M, Dobson CM, et al. (2003) Myoglobin
forms amyloid fibrils by association of unfolded polypeptide segments. Proc Natl
Acad Sci USA 100: 15463–15468.
53. Zandomeneghi G, Krebs MRH, Mccammon MG, Fandrich M (2004) FTIR
reveals differences between native b-sheet proteins and amyloid fibrils. Protein
Sci 13: 3314–3321.
54. Levine H, III (1993) Thioflavine T interaction with synthetic Alzheimer’s disease
beta-amyloid peptides: setection of amyloid aggregation in solution. Protein Sci
2: 404–410.
55. Naiki H, Higuchi K, Hosokawa M, Takeda T (1989) Fluorometric determina-
tion of amyloid fibrils in vitro using the fluorescent dye, thioflavin T1. Anal
Biochem 177: 244–249.
56. Stefani M, Dobson CM (2003) Protein aggregation and aggregate toxicity: new
insights into protein folding, misfolding diseases and biological evolution. J Mol
Med 81: 678–699.
57. Bucciantini M, Giannoni E, Chiti F, Baroni F, Formigli L, et al. (2002) Inherent
toxicity of aggregates implies a common mechanism for protein misfolding
disease. Nature 416: 507–511.
58. Bucciantini M, Calloni G, Chiti F, Formigli L, Nosi D, et al. (2004) Prefibrillar
amyloid protein aggregates share common features of cytotoxicity. J Biol Chem
279: 31374–31382.
59. Kayed R, Head E, Thomson JL, Mcintire TM, Milton SC, et al. (2003)
Common structure of soluble amyloid oligomers implies common mechanism of
pathogenesis. Science 300: 486–489.
60. Malmo C, Vilasi S, Iannuzzi C, Tacchi S, Cametti C, et al. (2006) Tetracycline
inhibits W7FW14F apomyoglobin fibril extension and keeps the amyloid protein
in a pre-fibrillar, highly cytotoxic state. FASEB J 20(2): 346–7.
61. Campioni S, Mannini B, Pensalfini A, Zampagni M, Parrini C, et al. (2010) The
causative link between the structure of aberrant protein oligomers and their
ability to cause cell dysfunction. Nat Chem Biol 6: 140–147.
62. Stefani M (2008) Protein folding and misfolding on surfaces. Int J Mol Sci 9:
2515–2542.
63. Cardin AD, Weintraub HJ (1989) Molecular modeling of protein-glycosamino-
glycan interactions. Arteriosclerosis 9: 21–32.
64. Cardin AD, Jackson RL (1998) Structural properties of the heparin-binding
domains of human apolipoprotein E. Adv Exp Med Biol 243: 157–163.
65. Multhaup G (1994) Identification and regulation of the high affinity binding site
of the Alzheimer’s disease amyloid protein precursor (APP) to glycosaminogly-
cans. Biochimie 76: 304–311.
66. Mok SS, Sberna G, Heffernan D, Cappai R, Galatis D, et al. (1997) Expression
and analysis of heparin binding regions of the amyloid precursor protein of
Alzheimer’s disease. FEBS Lett 415: 303–307.
67. Puett D (1973) The equilibrium unfolding parameters of horse and sperm whale
myoglobin. J Biol Chem 248: 4623–4634.
68. Bismuto E, Colonna G, Irace G (1983) Unfolding pathway of myoglobin.
Evidence for a multistate process. Biochemistry 22: 4165–4170.
69. Arrasate M, Mitra S, Schweitzer ES, Segal MR, Finkbeiner S (2004) Inclusion
body formation reduces levels of mutant huntingtin and the risk of neuronal
death. Nature 431: 805–810.
70. Bodner RA, Outeiro TF, Altmann S, Maxwell MM, Cho SH, et al. (2006)
Pharmacological promotion of inclusion formation: a therapeutic approach for
Huntington’s and Parkinson’s diseases. Proc Natl Acad Sci U S A 103(11):
4246–51.
71. Kvam E, Nannenga BL, Wang MS, Jia Z, Sierks MR, et al. (2009)
Conformational targeting of fibrillar polyglutamine proteins in live cells escalates
aggregation and cytotoxicity. PLoS One 4(5): e5727.
GAGs and Protein Aggregation
PLoS ONE | www.plosone.org 13 July 2011 | Volume 6 | Issue 7 | e22076